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Abstract
Background: Neonatal deaths, estimated at approximately 4 million annually, now account for almost 40 % of
global mortality in children aged under-five. Bacterial sepsis is a leading cause of neonatal mortality. Assuming the
mother is the main source for bacterial transmission to newborns, the primary objective of the trial is to determine
the impact of one oral dose of azithromycin, given to women in labour, on the newborn’s bacterial carriage in the
nasopharynx. Secondary objectives include the impact of the intervention on bacterial colonization in the baby and
the mother during the first month of life.
Methods/design: This is a Phase III, double -blind, placebo controlled randomized clinical trial in which 830
women in labour were randomized to either a single dose of 2 g oral azithromycin or placebo (ratio 1:1). The trial
included pregnant women in labour aged 18 to 45 years attending study health centres in the Western Gambia. A
post-natal check of the mother and baby was conducted at the health centre by study clinicians before discharge
and 8–10 days after delivery. Home follow up visits were conducted daily during the first week and then weekly
until week 8 after delivery. Vaginal swabs and breast milk samples were collected from the mothers, and the
pathogens Streptococcus pneumoniae, Group B Streptococcus (GBS) and Staphylococcus aureus were isolated from
the study samples. For bacterial isolates, susceptibility pattern to azithromycin was determined using disk diffusion
and E-test. Eye swabs were collected from newborns with eye discharge during the follow up period, and
Chlamydial infection was assessed using molecular methods.
Discussion: This is a proof-of-concept study to assess the impact of antibiotic preventive treatment of women
during labour on bacterial infections in the newborn. If the trial confirms this hypothesis, the next step will be to
assess the impact of this intervention on neonatal sepsis. The proposed intervention should be easily
implementable in developing countries.
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Background
The last decade witnessed a substantial reduction in the
risk of under-five child mortality [1–3]. However, the
greatest reduction occurred in children older than
1 month. Neonatal deaths, estimated at approximately 4
million annually, now account for almost 40 % of the
world’s deaths in children under-five [4] with approxi-
mately 75 % of these deaths occurring during the first
week of life [5]. The highest rates of mortality in this age
group occur in Sub-Saharan Africa (SSA).
Invasive bacterial disease, which mainly presents as
sepsis, is estimated to cause one out of three deaths in
this age group [5]. In the African continent, neonatal
sepsis is caused by a wide range of bacterial pathogens
[6] that differ between the early (first week of life) and
late (days 8 to 28) neonatal period. During the early neo-
natal period, when most neonatal sepsis occur [7], gram
positive bacteria predominate among sepsis case with
Staphylococcus aureus [5] and Streptococcus pneumoniae
being the most frequently bacteria isolated, closely
followed by group B Streptococcus (GBS) [6].
Vertical transmission from the mother plays an im-
portant role in early neonatal sepsis. Newborns may be
infected during labour as they pass through the birth
canal, or during the first hours/days of life through close
physical contact with the mother, if, as is commonly the
case in SSA, the mother carries pathogenic bacteria in
the nasopharyngeal tract or breast milk [5, 8–10].
Azithromycin (AZI) is a macrolide with a wide anti-
microbial spectrum; it is effective against organisms such
as macrolide-susceptible Staphylococcus species and
Streptococcus species [11]. AZI is currently licensed for
use in infants aged >6 months and is used to treat a wide
range of infections, including those occurring during
pregnancy [12, 13]. Data on the effect of treating preg-
nant women with up to 2 g of AZI for prevention of
malaria and preterm birth are available [12–16]. Al-
though scarce information exists, AZI appears to be ex-
creted in human milk at a very low concentration [17].
According to a case report, an infant who is exclusively
breastfed would receive approximately 1/10 or 1/20 of
the dose recommended in infants ≥6 months old [18].
Thus far, there are limited safety data on AZI in neo-
nates. Two trials among hospitalized neonates (one in-
cluding 111 low birth weight neonates admitted to
hospital and the other involved 2400 infants including ne-
onates) have not shown severe adverse reactions [19, 20].
In another published study, AZI was given to 58 newborns
as prophylaxis for pertussis [17] and only mild gastrointes-
tinal adverse reactions were observed [16]. No additional
adverse events were observed in the same study among
newborns from AZI treated mothers [17].
Orally administered AZI is widely distributed through-
out the body. In pregnant women, after one oral dose,
peak plasma concentrations are attained within 6 h;
myometrium concentrations reach high levels within this
time [21]. The elimination half-life from plasma and tis-
sues is 2–4 days. Some published literature show adverse
reactions (i.e. gastrointestinal, headache) or allergic reac-
tions (i.e. rash or swelling).
As part of the WHO-recommended trachoma control
strategy, mass AZI treatment campaigns have been carried
out in several trachoma endemic countries [22, 23], in-
cluding The Gambia [24]. The additional benefits of these
campaigns include decreased nasopharyngeal bacterial
carriage [25], and childhood morbidity and mortality [26].
In The Gambia, the prevalence of AZI resistance after
these mass AZI treatment campaigns was very low. For
example, among S.pneumoniae isolates collected 6 to
30 months after treatment, resistance ranged between
0.3 and 0.9 % [25]. The relevance of acquired macrolide
resistance for bacterial infections is uncertain but likely
to be minimal in settings like the Gambia (and other
African countries) where macrolides are very rarely used
as empirical antibiotic therapy. In addition, there is evi-
dence elsewhere from patients with cystic fibrosis receiv-
ing long term AZI, that although macrolide resistance
develops in S. aureus among treated patients, these
resistant organisms are not transmitted to their close
family contacts [27].
New interventions to decrease neonatal mortality are
urgently needed. If the mother is an important source of
bacterial transmission to the newborn, then an interven-
tion that reduces bacterial infections in the mother may
prevent bacterial transmission and neonatal sepsis. In
this study, we evaluate the impact of one oral dose of
AZI given during labour on the asymptomatic bacterial
carriage in the newborn baby as well as the mother. If
successful, this simple intervention could be easily im-
plemented at even the most remote health facilities. It
has the potential to achieve wide coverage in SSA where
low-cost interventions to reduce neonatal mortality are
urgently needed.
Methods/design
Study objectives
The primary objective of the trial is to determine the im-
pact of one oral dose of 2 g of AZI, given during labour,
on the newborn’s nasopharyngeal bacterial carriage at
the age of 6 days for at least one of three pathogens:
S.aureus, GBS and S. pneumoniae.
Secondary objectives are to determine the impact of
the intervention on bacterial carriage in the nasopharyx
of the baby, and in the vaginal tract and breast milk of
the mother at different time points within the first
4 weeks after delivery. The impact of AZI on purulent
conjunctivitis and ocular C. trachomatis infection will
also be assessed.
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To evaluate the safety of the intervention on mothers
and newborns we monitored and assessed adverse events
(AE). Special attention was paid to hypertrophic pyloric
stenosis (HPS) in the newborn which is usually reported
as projectile vomiting.
Study endpoints
The primary endpoint is the prevalence of nasopharyn-
geal carriage of the newborn at the age of 6 days for any
of the following bacteria: S.aureus, GBS and
S.pneumoniae.
Secondary endpoints include:
– Prevalence of nasopharyngeal bacterial (S.aureus,
GBS and S.pneumoniae) carriage of the newborn at
different time-points during the first months of life.
– Prevalence of nasopharyngeal, vaginal and breast
milk bacterial carriage (S.aureus, GBS and
S.pneumoniae) of the mother at different time-
points during the first month after delivery.
– Prevalence of non-susceptibility to macrolides
among bacteria (S.aureus, GBS and S. pneumoniae)
isolated from the clinical samples collected from the
newborns and their mothers during the first month
after delivery.
– Proportion of newborns with at least one episode of
purulent conjunctivitis and ocular C. trachomatis
infection within the first week of life, the first
4 weeks of life and during the 8 weeks of the follow-
up period.
We also measured AZI concentrations in the breast
milk of the first 40 women recruited into the trial at two
time points during the first week of life . Other end-
points not initially included in the protocol are weight
gain during the first 8 days of life and the time from
BCG vaccination to the appearance of a scar.
As safety endpoints, we included the number of soli-
cited and unsolicited AEs in mothers and newborns ob-
served during the first 6 days after treatment; and
number of AEs in mothers and newborns reported dur-
ing the first 8 weeks after treatment.
Trial design
This is a Phase III, double -blind, placebo controlled
randomized clinical trial in which pregnant women in
labour attending study health facilities centre were ran-
domized to either a single dose of 2 g of oral AZI or pla-
cebo (ratio 1:1).
Blinding and Un-blinding
The packaging and labelling of the interventional med-
ical product (IMP) was conducted by IDIFARMA. AZI
and placebo were provided as tablets packed in blisters.
The randomisation list was created by an independent
statistician/data manager and IDIFARMA numbered the
blisters according to the list. One blister pack of IMP
contained four tablets of 0.5 g of AZI or placebo (2 g in
total). The active drug and the placebo looked identical
and were not identifiable.
Sealed envelopes containing the individual treatment
allocation were kept at the study site for emergency
cases. The code could be broken for individual partici-
pants in cases of AE for which the investigational prod-
uct needed to be known. The code was kept for the
entire study period by the independent statistician of the
Data Safety Monitoring Board (DSMB) and will be
broken only after the database lock.
Study setting
The study was conducted in a peri-urban area situated
on the western margin of The Gambia, approximately
20 km from the capital Banjul. The population includes
the main ethnic groups in The Gambia, engaged in a
wide range of occupations, including working for gov-
ernment services, liberal professions and trading. The
climate of the area is typical of the sub-Sahel region,
with a long dry season from November to May and a
short rainy season between June and October. Much of
the population is illiterate [2].
The study was carried out in the Jammeh Founda-
tion for Peace Hospital (JFPH), a government-run
health centre located approximately 8 km from Fajara
where the main MRC laboratories are based. This
health centre serves a local community of more than
50,000 inhabitants and a large catchment area with
several neighbourhoods; and manages approximately
5,000 deliveries per year (Fig. 1).
Ethical considerations
All study mothers had signed consent during their pre-
natal visits before being enrolled into the trial. A local
safety monitor (LSM) and a Data Safety Monitor Board
(DSMB) reviewed all the SAE during the course of the
trial, and the trial was monitored by an independent
clinical trials monitor. The study was approved by the
joint Medical Research Council (MRC)/Gambia Govern-
ment Ethics Committee.
Sensitization and consenting
Community sensitization
Initial sensitization of community leaders was done dur-
ing an Open Day at JFPH. During the process of com-
munity sensitization, the study field team asked the
community leaders to identify literate six people from
the community who would be willing to act as impartial
witnesses.
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Identification of pregnant women
A field worker explained the study to pregnant women
attending the JFPH for antenatal care and planning to
deliver their babies there. The explanation occurred
soon after the women had received the standard health
education talk from the nursing staff in charge of the
antenatal clinic.
Women sensitization
Interested women were invited to the field team office
where the study explained in their preferred language.
After obtaining the woman’s agreement, a unique
sensitization sticker was placed on her antenatal card.
During the course of the study, awareness of the nature
of the study, increased steadily as the message had
spread within the community.
Consenting
After sensitization, an individual consenting process was
started. The informed consent form (ICF) could only be
signed at JFPH. Mothers either signed the ICF or, if they
were illiterate, thumb printed it. An impartial witness
was present during the consenting process for illiterate
women.
Women were encouraged to ask questions during con-
senting. If the field worker could not answer questions
raised by the women, either the nurse coordinator or a
study clinician was then involved in the process. The
woman’s understanding of the information was tested
using an informed consent understanding tool question-
naire with 13 questions. A maximum of two attempts
were allowed; the consenting process was stopped if
after a second attempt at least one of the questions was
not correctly answered (Fig. 2). The completed ICF was
Fig. 1 Study site
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attached to the woman’s antenatal card and a copy was
kept securely in the study office.
Pregnant women were informed that signing/thumb
printing the ICF did not automatically result in being
enrolled in the study; this occurred only if the woman
delivered at the study site at the time the study nurses
were available to screen, randomize and treat them.
Screening, recruitment and randomization
Screening
When women presented to the labour ward in labour, a
study nurse confirmed she had signed consent and
assessed the continued willingness of the women to par-
ticipate in the study. Subsequently, eligibility was deter-
mined using the criteria detailed below.
 Inclusion criteria: Pregnant women in labour aged
18 to 45 years presenting to the JFPH for delivery
 Exclusion criteria
– Known HIV infection
– Any chronic or acute condition that might
interfere with the study as judged by the research
clinician
– Planned travel out of the catchment area during
the 2 months after delivery (follow-up period)
– Planned caesarean section
– Known required referral
– Known multiple pregnancy
– Known severe congenital malformation of the
baby
– Intrauterine death confirmed before
randomization
Fig. 2 Sensitisation and Informed Consent Understanding Tool Process
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– Known allergy to macrolides
– Intake of antibiotics in the week before
randomization
Recruitment
Once eligibility was determined, baseline or pre-
intervention samples were collected from the mother
[nasopharyngeal swab (NPS) and vaginal swab].
Randomization
IMP were labelled from 001 to 830. A random con-
trol digit was added to the identification number after
a backslash – e.g. 001/1, to help detect transcription
errors. The IMPs were assigned consecutively and in
ascending order. The time when the drug was taken
was recorded. The randomization number on the spe-
cific blister was written in the spaces (− − − / −) pro-
vided on the particular page of the case report form
(CRF). Any vomiting (if it occurred), was documented
including the timing and whether an IMP tablet was
seen in the vomitus.
Health centre discharge, follow up and sampling (Table 1
and Fig. 3)
Women were kept under close observation by study
nurses. The JFPH nurses conducted the delivery. When
the baby was born, the study nurse on duty collected the
NPS within 6 h of birth. A clinical examination of both
mother and baby were carried out by one of the study
clinicians before discharge (Table 1), which occurred 6
to 24 h (mostly within 6–10 h) after delivery if both
were clinically stable and there were no serious adverse
events (SAE). Then, participants were given a Participant
Identification (ID) card for further identification.
Home visits were conducted for each mother/baby
pair for 8 weeks. In the first week, a nurse followed-
up both mother and baby with daily recording of in-
formation on the health status of the pair and any
adverse events (AE). During this week, samples were
collected on days 3 and 6, including NPS from
mother and baby and breast milk from the mother
(Table 1).
Between the 8 and 10 days after the delivery, both
mother and baby presented at the study site where
the research clinician evaluated them and a vaginal
swab was collected from the mother (Table 1). At
that point, the babies presented at the infant welfare
clinic to receive their BCG, OPVo, and Hepatitis B
vaccines.
During the next 7 weeks, a field worker followed up
the mother/baby pair. At weeks 2 and 4, breast milk
samples were collected from the mothers and NPS from
both mothers and babies (Table 1). If the baby was noted
to have eye discharge during any of the visits, an eye
swab was collected and clinical information recorded.
Treatment was given appropriately.
In the advent of any symptoms or signs of illness dur-
ing home visits, the field worker called the nurse coord-
inator who, if necessary, asked the mother and baby to
go to the study site to be assessed by the nurse coordin-
ator or his assistant or when indicated, by the study
clinicians.
If during the follow-up period, either mother or baby
needed antibiotics, samples were collected in lieu of the
next scheduled sample and participants were started on
antibiotics. If a mother was on antibiotics, no more sam-
ples were collected from her or the baby. If the baby was
on antibiotics, subsequent samples were still collected
from the mother.
Table 1 Summary of the study activities including follow up visits and sampling
Visit number Pre-intervention Post-intervention
Day 0
(delivery)
Day 0
(delivery)
Day 1 to 6 Week 1
(days 8–10)
Week 2 Week 3 Week 4 Week 5 to 8
Window period — —— 1 day Day 6 to 13 −2/+4 days −3/+3 days −3/+3 days −3/+3 days
Health Centre visit X X X
Home follow-up visits X X X X X
Informed consent X
Review inclusion/exclusion criteria X
Adverse events X X X X X X X X
NPS mother X Xa X X
NPS newborn X Xa X X
Breast milk sample Xa X X
Vaginal swab X X
aOnly days 3 and 6
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The last field worker visit occurred 8 weeks after birth.
This marked the study termination date for the mother/
baby pair.
Safety considerations and serious adverse events
(SAEs)
Safety of the trial
A local safety monitor (LSM) and a Data Safety Monitor
Board (DSMB) who reviewed all the SAE during the
course of the trial was established.
Referral procedures for SAE
Any AE for either a mother or a baby, was captured in
the CRF. When a study baby visited JFPH with any ill-
ness or called the nursing team, s/he was initially seen
by the nurse on duty who determined the need for the
baby to be reviewed by the study physician at the health
centre. If referral was needed, the clinician recorded and
instituted initial management of the child’s condition be-
fore subsequently referring him/her to the MRC ward in
Fajara or the Edward Francis Small Teaching Hospital
(EFSTH) in Banjul. Study related procedures (such as
daily/weekly visits) continued as per protocol.
Hypertrophic pyloric stenosis (HPS)
Because of the lack of information on breast milk
trespass of AZI and effects of AZI in the newborn,
there was a risk of HPS. Field workers and nurses
were trained to recognise HPS through abdominal
palpation and auscultation. In the event of a sus-
pected HPS case or severe vomiting reported by the
mother, study staff were advised to immediately in-
form the study clinicians and PI. Subsequently, the
child was to be transferred to the MRC Ward in
Fajara for a thorough clinical assessment. The follow-
ing steps were put in place:
Fig. 3 Overall study approach
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– Diagnosis by the research clinician using clinical
judgement and conducting laboratory (electrolytes)
and imaging studies such as abdominal x-ray to
eliminate other potential diagnoses.
– If necessary, transfer to the EFSTH, in Banjul, where
surgical review and additional assessment could be
performed, including ultrasound if deemed
necessary to confirm HPS diagnosis.
If the diagnosis of HPS is confirmed, the definitive
treatment is surgical.
Samples and laboratory methods
Sample collection
Clinical or field staff who received training on sample
collection as per study protocol were involved in the col-
lection of the following samples:
Nasopharyngeal Swabs (NPS) were collected by insert-
ing a calcium alginate (Expotech USA Inc) swab into the
posterior wall of the nasopharynx. The swab was rotated
and left in the nasopharynx for approximately 5 s. The in-
oculated swab was placed immediately into a vial contain-
ing skim milk-tryptone-glucose-glycerol (STGG) transport
medium and then into a cold box before transporting to
the MRC Laboratories within 8 h, in accordance with the
WHO protocol for evaluation of bacterial carriage [28].
Low Vaginal swabs (VS) were collected by inserting a
sterile cotton swab (Sterilin Ltd, UK) 2–3 cm into the
vagina and rotating the swab with a circular motion,
leaving it in the vagina for approximately 5 s. The inocu-
lated swabs were then placed immediately into the vials
containing STGG and put in a cold box before being
transferred to the MRC Laboratories within 8 h.
Breast milk samples
The nipple and areola of the breast from which milk was
taken was disinfected using sterile cotton soaked with
0.02 % chlorhexidine. Mothers were then asked to
manually express their milk. The first 0.5 mL were dis-
carded. The following 1-2 mL was collected in another
sterile plastic bijoux bottle put in a cold box and trans-
ferred to the MRC Laboratories within 8 h.
Eye swabs were collected using a sterile cotton swab
(Sterilin Ltd, UK). The lower eyelid was pulled down to
expose the conjuctival sac inside the lower eyelid. The
sterile cotton swab was rolled on the conjuctival sac,
parallel to the cornea to avoid injury. The inoculated
cotton swabs were immediately returned to its container,
put in a cold box and transported to the MRC Labora-
tories within 8 h.
Bacteriological analysis for NPS, VS and BM samples
Samples received in the lab were vortexed for 20 s be-
fore being stored at −70 °C for subsequent processing in
batches. During processing, samples were allowed to
thaw on ice. Each vial was then vortexed briefly in order
to homogenise the medium and 50 μl was dispensed
onto gentamicin blood agar (GBA) (CM0331 Oxoid, UK
+5 % sheep blood), mannitol salt agar (MSA)(CM0085
Oxoid, UK) and crystal violet blood agar
(CVBA)(CM0085 Oxoid, UK +0.02 % crystal violet) for
selective isolation of S. pneumoniae, S. aureus and GBS
respectively. Each inoculum was streaked onto four
quadrants in order to semi-quantitatively determine the
bacterial load [29]. Colony density was determined by
recording growth of alpha-haemolytic colonies (GBA
plates), yellowish dome shaped colonies (MSA plates)
and beta haemolytic colonies (CVBA plates) as 4+ if >10
colonies are present in quadrant 4, 3+ if there are <10
colonies in quadrant 4 and > than 10 colonies in quad-
rant 3, 2+ if there are <10 colonies in quadrant 3 and >
than 10 colonies in quadrant 2, and 1+ if there are less
than < 10 colonies in quadrant 1.
Streptococcus pneumoniae
After 20–24 h incubation at 37 °C with 5 % CO2, GBA
plates were examined for typical alpha haemolytic col-
onies. A single colony was picked and sub-cultured onto
another Blood agar (BA) to obtain pure growth and
screened for optochin susceptibility [28]. Zones of inhib-
ition ≥14 mm indicate susceptibility, 7–13 mm were
intermediate and <7 mm indicate resistance to optochin
(WHO protocol). Optochin susceptible isolates were
confirmed pneumococci; those of intermediate suscepti-
bility were confirmed by the bile solubility test. Those
that are optochin resistant were considered to be species
other than pneumococcus.
Pneumococcal latex serotyping
Pneumococcal serotyping was performed as described
previously [30]. In brief, pneumococcal cell suspension
was made in 2 ml normal saline (1.0 McFarland) from
an overnight culture. 50 μl of the cell suspension was
dispensed into ten wells of the serotyping tray. An
equivalent amount of each of the main group latex anti-
sera (A, B, C, D, E, F, G, H, I and Omni) was added to
the wells. The mixture was rugged for a maximum of
2 min and agglutination(s) observed in the wells. The
procedure was repeated with the sub-groups of the main
groups in which agglutination was observed. The sub-
groups that reacted were further typed with the corre-
sponding subtypes and the agglutinations noted. The
resulting serotype was determined with the aid of a chart
(Statens Serum Institute, Denmark).
Staphylococcus aureus
After forty-eight hour incubation at 37 °C, MSA plates
were examined for typical staphylococci colonies. Pale to
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golden yellow domed shaped colonies 1–2 mm in diam-
eter were cultured onto Blood agar to obtain pure
growth. Catalase test was performed on all suspected
colonies and catalase positive colonies were further
tested using the coagulase test. Isolates positive for co-
agulase test were confirmed to be S. aureus.
Group B streptococci
After 20–24 h incubation, presumptive beta-haemolytic
colonies were streaked onto BA agar to obtain pure
growth. Catalase test was performed using hydrogen per-
oxide to quickly differentiate the presumptive Streptococci
from Staphylococcus species. Beta-haemolytic and catalase
negative isolates confirmed to be streptococci were
grouped using the Streptex grouping kit (Remel
R30950501) and ultimately reported as A, B, C, D, F or G.
Antibiotic susceptibility testing
Between 3 and 5 well-isolated colonies of similar mor-
phological appearance were transfered into 2.5 ml
physiological saline until visible turbidity equal to 0.5 %
McFarland’s Standard was obtained. A sterile swab was
then immersed into the suspension and then streaked
evenly over the surface of the Mueller Hinton agar
(MHA) with 5 % sheep blood (S. pneumoniae and GBS)
and MHA without blood (S. aureus) in three directions,
rotating the plate 90 °C to ensure even distribution.
Azithromycin resistance was screened by disk diffusion
(15 μg azithromycin disc) and those intermediated or re-
sistant were determined by E-test following the clinical
and laboratory standard institute (CLSI) 2014 guidelines
for the performance of test and interpretation of results:
(i) S.aureus isolates with E-test values ≥8 μg/ml were re-
ported as resistant whilst values <8 μg/ml ≥ 4 μg/ml as
intermediate resistant; (ii) S. pneumoniae/GBS isolates
with E-test values ≥2 μg/ml were reported as resistant
whilst values <2 μg/ml ≥ 1 μg/ml as intermediate
resistant.
Molecular analysis for ocular swabs
DNA was extracted from all ocular swabs using the
QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany) ac-
cording to the manufacturer’s instructions. The presence
of C. trachomatis DNA was assayed for using the FTD
Vaginal Swab kit (Fast-track Diagnostics, Junglinster,
Luxembourg) on a RotorGene 6000 real-time PCR cycler
(QIAGEN, Hilden, Germany). Samples were further tested
for the presence of C. trachomatis DNA using the droplet-
digital PCR method as described by Roberts et al. [31].
Azithromycin measurement
AZI levels were measured using a validated liquid
chromatography-mass spectrometry (LC-MS) method
using a triple quadrupole MS (8030 plus, Shimadzu,
Kyoto, Japan) and a deuterated internal standard. In
brief, 20 μL samples of milk were spiked with internal
standard and extracted based on methodology developed
for plasma samples (Salman et al. Antimicrob Agents
Chemother 2010;54: 360–366). After addition of ammo-
nium hydroxide and methanol, vortex mixing and freez-
ing, the thawed sample was centrifuged and the organic
supernatant mixed with water and an aliquot injected
onto an Agilent Eclipse plus C18 column (Agilent
Technologies, Santa Clara, CA). MS quantitation was
performed in multiple reaction monitoring mode using
an ESI+ ion source. Matrix effect, process efficiency and
absolute recovery for AZI and AZI-d3 were within ac-
ceptable ranges (means 92.5 to 107.9 %). Intra- and
inter-day relative standard deviations were 3.1–5.2 and
6.6–9.7 %, respectively, at AZI concentrations between
100 and 5000 μg/L. Mean accuracy was between 94.5
and 103.8 % over the same concentration range. The
limits of quantitation and detection were 5 μg/L and
2.5 μg/L, respectively.
Data considerations
Data handling and record keeping
Each participant pair had a unique identification (ID)
number. All data recorded on individuals used the an-
onymous ID. All forms with subject names is kept in a
locked cabinet, when not in use. Clinical data is stored
separately from that containing personal information.
Data will be stored for at least 10 years. The informed
consent forms and source documents will be stored,
after study completion, in a confidential archive; they
will be stored separately from the study documents in
the access-restricted archive at the MRC Unit.
Some sections of the CRFs act as source data for the
trial and are completed directly by the relevant research
personnel. A few sections, such as vaccination, are tran-
scribed from the Infant Welfare Card for the newborn.
Other information from the mother and the baby (such
as age of the mother or birth weight of the baby) was
transcribed from the antenatal card. Other source data
include: the structured clinical notes at enrollment, dis-
charge and post-natal visit, and the structured informa-
tion collected from field workers/nurses during the
weekly home visits (week 2 to week 8). At each visit, a
CRF was completed by the relevant study team member.
In addition, laboratory forms were also completed for
any sample collected as part of the study from either the
mother or the baby.
CRF data is entered into an OpenClinica (www.open
clinica.com) database using double data entry and verifi-
cation. Laboratory data have been recorded on lab forms
designed specifically for the study and entered into a
separate site within the OpenClinica study database.
Screening information was entered in another sub-
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database within the main OpenClinica database. Screen-
ing records are uniquely identified by the sensitization
number, which is issued at the time of sensitization.
Consistency checks have been performed during data
entry and outliers and missing data checked against the
original forms then subsequently amended in the
database.
The PI and sponsor maintain appropriate medical and
research records for this study in compliance with ap-
plicable Good Clinical Practice (GCP), regulatory and in-
stitutional requirements. Authorised representatives of
the sponsor, the ethics committee or regulatory bodies
may inspect all documents and records maintained by
the investigator. The PI or designee ensures access to fa-
cilities and the records.
The PI or designee documented and explained any de-
viation from the approved protocol and reported them
to the sponsor and ethics committee in accordance with
the MRC Unit’s standard procedures.
At study closure, all items on the following checklist
will be checked prior to locking the database:
 All expected study subjects have been entered
 Checks for any duplicate subjects is negative
 SAE reconciliation has been completed
 Protocol Deviation reconciliation has been
completed.
 All final cleaning checks have been performed and
all outstanding issues resolved
 Approval for database lock has been obtained from
the Head of Data Management (HoDM), the
statistician, and the PI.
 Database access rights have been removed.
The randomisation list will be kept by the statistician
of the DSMB until the blinded results of the statistical
analysis are available. The study site will retain a set of
envelopes containing the allocation of each subject so
that individuals can be unblinded for safety reasons
without accessing the randomization list.
Trial monitoring
A clinical trials monitor independent from the investiga-
tor team monitored the trial. The monitor conducted an
initiation visit to the site before the trial started to verify
and document that all study staff were adequately in-
formed about the study and that the IMP to be used had
been received and stored accordingly on site.
During the course of the trial, interim monitoring
visits took place at the health centre, the IMP storage fa-
cility, the site office and the laboratories.
During the visits, the monitor carried out a quality
control of trial progress in respect to protocol and oper-
ating guidelines, data collection, completion of consent
forms, completion of study documents, SAE reporting,
and samples and IMP management. Source data verifica-
tion was conducted for all ICFs, eligibility criteria and
SAEs.
The monitor inspected up to 10 % of participants
CRFs for accuracy, completeness and consistency with
source documents before data entry and reviewed the
investigator’s file.
At the end of each monitoring visit, the monitor dis-
cussed the findings with the study team and outlined
what further actions should be taken.
The Monitor will conduct a close-out visit after all
data queries have been resolved and the data base has
been locked to ensure that all essential documents are
completed and filed accordingly and are ready for ar-
chiving, that all IMPs have been accounted for and are
returned to supplier or destroyed accordingly, and that
all unused study materials are returned to suppliers or
destroyed, as applicable.
The study team established, in addition, internal moni-
toring procedures to ensure review of all CRFs by study
team members before any data was entered into the
database.
Sample size rationale
The original sample size (415 mother/baby pairs per
arm) assumed a 15 % loss to follow-up (i.e. 353 partici-
pants in each arm for whom the primary endpoint is re-
corded). Based on data from a previous study [32],
bacterial carriage (S.aureus, GBS or S.pneumoniae) on
day 6 was assumed to be 60 % in the control arm. Ac-
cording to these assumptions, the study has 98 % power
to detect a 25 % reduction in bacterial carriage (GBS,
S.pneumoniae or S.aureus) and 88 % power to detect a
20 % reduction.
Statistical analysis
A flow chart will be used to describe the number of
mothers who were eligible, randomised and treated, and
the number of samples obtained from mothers and chil-
dren at each time point.
The adequacy of the randomisation procedure will be
checked by comparing baseline characteristics of
mothers (ethnicity, age, season enrolled, hours from
treatment to delivery, mode of delivery, time to rupture
of membrane, apgar score, multiple pregnancy) and
newborns (sex, birth weight, gestational age) between
arms. Some of these variables are measured post inter-
vention, but are unlikely to be influenced by the inter-
vention (time from treatment to delivery, mode of
delivery, time to rupture of membrane, Apgar score).
Prevalence of bacterial carriage in the mother pre-
intervention will also be used to check comparability of
baseline characteristics (NPS and vaginal swab).
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The primary analysis will be based on intention to
treat (ITT). We will include data on twins but will not
adjust for the effect of clustering (the average cluster size
will be close to 1 so the design effect will be negligible).
A per protocol analysis will be conducted excluding
samples from mothers who vomited less than 15 min
after medication was taken, samples collected after the
use of antibiotics, and samples arriving at the lab more
than 8 h after collection.
The prevalence of bacterial carriage will be compared
between arms at each time point (in NPS, vaginal swabs
and breast milk). The prevalence of carriage will be pre-
sented separately for each species and combined (i.e.,
carriage of S.aureus, GBS or S.pneumoniae). In addition,
carriage acquisition rates will be compared between
arms for the periods 0–6 days and 7–28 days (acquisi-
tion will happen when a non-carrier will become carrier
in the subseuqent sample). Ratios of prevalence and
95 % confidence intervals will be calculated for each of
these comparisons, and Fisher’s exact test will be used to
compute p-values for the comparisons of prevalence.
A Poisson regression model will be used to assess the
effect of the intervention on prevalence of carriage
across all time points. The model will include time,
baseline carriage status of the mother, mother’s age, eth-
nicity, season, sex of the newborn, and gestational age.
Robust standard errors will be used to account for the
dependence between observations from the same indi-
vidual as well as the model misspecification (carriage
status is binary and therefore does not follow a Poisson
distribution).
To calculate prevalence of carriage at day 3 and day 6
we will use data from samples (NPS newborns and
mothers, breast milk) collected within 1 day of the
scheduled visit. At 14 days we will use samples collected
between 12 and 18 days, and at 28 days we will use sam-
ples collected between 25 and 31 days. For vaginal bac-
terial carriage at day 8–10 we will use samples collected
between 7 and 13 days. Samples were not collected after
children received antibiotics. Where a sample was col-
lected in lieu of the missing sample (i.e., before antibi-
otics were given) this will be used in place of the missing
sample, even if it was collected outside the appropriate
window period.
We will present analyses based on the available data.
For the primary outcome we will conduct two additional
analyses using the ITT cohort. First, a subgroup analysis
in women who gave birth 2 h or more after taking the
drug. And second, a sensitivity analysis using multiple
imputation of missing data. In the imputation model,
bacterial carriage in missing samples will be imputed
from data on bacterial carriage at other time points and
baseline demographic data (age and ethnicity for
mothers, and sex and birth weight for newborns).
Changes in prevalence of bacterial carriage over time
will be plotted for NPS in mothers and newborns, and
breast milk. The plots will include point-wise 95 % con-
fidence intervals for each prevalence estimate.
The numbers and rates of adverse events, serious ad-
verse events (overall and specifically with a diagnosis of
neonatal sepsis), purulent conjunctivitis, Chlamydial
conjunctivitis, and deaths in newborns will be reported
by trial arm. Rates of adverse events and serious adverse
events will be reported in mothers. Rates will be com-
pared between trial arms using Poisson regression, and
robust standard errors will be used to allow for hetero-
geneity in the rates between individuals.
Discussion
Neonatal deaths, estimated at approximately 4 million an-
nually, represent up to 40 % of all child fatalities with 3
out of 4 of these neonatal deaths occurring during the first
week of life with maximum risk during the first 3–4 days.
Interventions designed to impact on child mortality
should target this vulnerable age group.
Sepsis causes up to 1 out of 3 neonatal deaths. Many
neonatal casualties associated with sepsis are preventable
when appropriate interventions are put into place. In
resource-rich countries, GBS infections were substan-
tially reduced with antibiotic-based prevention strategies.
For example, chemoprophylaxis with ampicillin or peni-
cillin in the USA reduced the incidence of early onset
neonatal sepsis caused by GBS from 1.8 per 1,000 live
births in the early 90’s to 0.28 per 1,000 in 2010 [33]. In
these countries, when a screened woman is identified as
a GBS vaginal carrier, she is treated during labour intra-
venously with antibiotics [33, 34]. To reach maximum
effectiveness, treatment should last at least 4 h before
delivery [33, 34]. Maternal antibiotic treatment during
labour blocks bacterial transmission to the newborn at
birth. Because the newborn does not become infected, s/
he is not at risk of developing early neonatal severe dis-
ease. Before GBS screening was introduced in USA and
other developed countries, the great majority of neonatal
sepsis, especially those occurring during the early neo-
natal period, were caused by this bacterium.
To roll-out a potentially successful intervention to de-
veloping countries within Africa and elsewhere, main
epidemiological and contextual differences between the
regions need to be considered. Unlike developed coun-
tries, several bacteria are associated with early and late
neonatal sepsis in the African continent and intravenous
antibiotics are generally unavailable. Approximately two
thirds of neonatal sepsis cases in Africa are caused by
gram positive bacteria [9] and in some countries gram
positive bacteria represent up to 80 % of all sepsis during
the first month as well as the first week of life. Due to
costs, limited infrastructure and diagnostic facilities,
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screening programmes are difficult to implement in SSA
and other developing regions. Still, screening may not be
needed where at least half of pregnant women are vagi-
nal carriers of one of the most common bacteria associ-
ated with neonatal sepsis [35]. In Africa, other known
risk factors for early neonatal sepsis, such as preterm or
low birth weight [7] and premature rupture of mem-
branes or prolonged labour [36], are also common.
The relevance of acquired macrolide resistance for
outcome of episodes of clinical infection is uncertain,
but is likely to be minimal in a setting like the Gambia
and other African countries where macrolides are very
rarely used as empirical antibiotic therapy. Also, previ-
ous studies in The Gambia show that after mass AZI
campaigns for trachoma control, prevalence of AZI re-
sistance among S.pneumoniae isolates was re-establisehd
to baseline levels (<1 %) [25]. In addition, there is evi-
dence elsehwere from patients with cystic fibrosis receiv-
ing long term AZI, that although macrolide resistance
develops in S. aureus among treated patients, these re-
sistant organisms are not transmitted to their close fam-
ily contacts [27].
In this proof-of-concept study, we propose an inter-
vention that would be easily implementable in develop-
ing countries. We treat women in labour attending a
health facility with one dose of AZI, an oral antibiotic
that is cheap and does not need specific storage condi-
tions (can be kept at room temperature), and we will as-
sess whether this antibiotic decreases the risk of
bacterial colonization in the baby during the neonatal
period (primary endpoint during the first week of life or
early neonatal period) and the mother during the same
period. The hypothesis that motivates our intervention
is that the mother is the main source of bacterial trans-
mission to the baby. If the intervention is successful in
proving our hypothesis, then we will design several add-
itional studies. First, we will assess the impact of the
intervention on severe clinical endpoints such as neo-
natal sepsis and mortality in the baby and puerperal sep-
sis in the mother. If this is shown to be of benefit, we
will then test the intervention in the context of home
delivery, as in Africa, many women deliver at home
attended by traditional birth attendants.
Trial status
At the time of submission of this manuscript, ethical ap-
proval had been obtained and recruitment had finished.
Laboratory work and data cleaning was ongoing.
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